Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Synchron Announces $75M Series C Round

2022-12-15
NEW YORK, NY, Synchron, the endovascular brain-computer interface (BCI) company, announced today an oversubscribed $75 million Series C financing round led by ARCH Venture Partners.
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors. Existing investors, including Khosla Ventures, NeuroTechnology Investors, METIS, Forepont Capital Partners, ID8 Investments, Shanda Group and University of Melbourne participated in the round. The Series C funding brings the total amount raised since inception to $145 million.

Synchron is a clinical-stage endovascular brain computer interface (BCI) company. Since 2012, the company has been developing a BCI platform that avoids the need for open brain surgery by using a minimally-invasive procedure. The Synchron Switch™ BCI received FDA Breakthrough Device Designation in 2020, and is currently in human clinical trials in the US and Australia. Synchron has been published in multiple peer-reviewed journals including Nature Biotechnology, Nature Biomedical Engineering and JNIS.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors